Work

Complete Resolution of Granulomatous Rosacea With Topical Ruxolitinib

Year: 2025

Type: article

Abstract: Granulomatous rosacea (GR) is a rare and challenging subtype of rosacea that resists conventional therapies. Here, we present the case of a 56-year-old woman with a two-decade history of treatment-refractory GR who experienced significant clinical improvement with topical ruxolitinib, a Janus kinase (JAK) inhibitor, formulated as a 1.5% cream applied twice daily. After failing multiple established treatments, the patient achieved near-complete resolution of her condition following 10 months of combination therapy with topical ruxolitinib and metronidazole cream. This case highlights the potential efficacy of topical JAK inhibitors as a novel therapeutic approach for recalcitrant GR.

Source: Cureus

DOI: 10.7759/cureus.82457

Authors: Jeffrey D Weiner, Sara Khoshniyati, Olivia Pierog, Sima Rozati

Institutions: Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Acne and Rosacea Treatments and Effects

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4409528954